Acrux Ltd (ASX: ACR) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Acrux Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $34.04 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 283.68 million
Earnings per share -0.063
Dividend per share N/A
Year To Date Return -27.27%
Earnings Yield N/A
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Acrux Ltd (ASX: ACR)
Latest News

Dividend Payment History Data provided by Morningstar.

Data provided by Morningstar.
Ex-Date Amount Franking Type Payable
18 Aug 2015 $0.0600 100.00% 03 Sep 2015
04 Sep 2014 $0.1300 61.54% 22 Sep 2014

ACR ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Acrux Ltd

Acrux Limited (ASX: ACR) is a Melbourne-based company specialising in the development of pharmaceutical treatments administered through the skin. Incorporated in 1998, Acrux was granted its first United States patent in 2001.

Acrux operates its own in-house laboratories and manufacturing facilities from which it develops and commercialises products for sale via licensees across the US, Europe and other international markets.

The company’s two key products are Axiron® and Estradiol MDTS. Axiron is a topical testosterone solution used to treat men suffering with various forms of clinically diagnosed testosterone deficiency. It is applied to the skin on the armpits. Generic versions of this product were launched in the US and, as a result, Acrux withdrew Axiron from the US market in September 2017, citing that it was ‘no longer commercially viable’. Estradiol MDTS was the company’s first product and is transdermal spray used to treat hot flushes associated with menopause.

The Acrux share price first listed on the ASX in 2004 and reached levels above $4 between 2011 and 2013. Since then, the Acrux share price has largely trended downwards and has spent the majority of the period from 2017 to 2020 trading below 20 cents.

ACR Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
20 Oct 2021 $0.12 $0.00 0.00% 189,216 $0.12 $0.12 $0.12
19 Oct 2021 $0.12 $0.00 0.00% 42,800 $0.12 $0.12 $0.12
18 Oct 2021 $0.12 $0.00 0.00% 100,000 $0.12 $0.12 $0.12
15 Oct 2021 $0.12 $0.00 0.00% 50,346 $0.12 $0.12 $0.12
14 Oct 2021 $0.12 $0.00 0.00% 848,175 $0.12 $0.13 $0.12
12 Oct 2021 $0.12 $-0.01 -8.00% 1,493,008 $0.13 $0.13 $0.12
11 Oct 2021 $0.13 $-0.01 -7.69% 229,393 $0.13 $0.13 $0.12
08 Oct 2021 $0.13 $0.00 0.00% 136,500 $0.13 $0.13 $0.13
07 Oct 2021 $0.13 $0.00 0.00% 69,326 $0.13 $0.13 $0.13
06 Oct 2021 $0.13 $0.00 0.00% 165,176 $0.13 $0.13 $0.13
05 Oct 2021 $0.13 $0.00 0.00% 61,000 $0.13 $0.13 $0.13
04 Oct 2021 $0.13 $-0.01 -7.69% 612,060 $0.13 $0.13 $0.13
01 Oct 2021 $0.13 $0.01 8.00% 10,002 $0.13 $0.13 $0.13
30 Sep 2021 $0.13 $-0.01 -7.69% 30,000 $0.13 $0.13 $0.13
29 Sep 2021 $0.13 $0.00 0.00% 178,792 $0.12 $0.13 $0.12
28 Sep 2021 $0.13 $0.00 0.00% 25,403 $0.13 $0.13 $0.13
27 Sep 2021 $0.13 $0.01 8.33% 150,915 $0.12 $0.13 $0.12
24 Sep 2021 $0.12 $0.00 0.00% 366,408 $0.13 $0.13 $0.12
23 Sep 2021 $0.12 $0.00 0.00% 297,795 $0.13 $0.13 $0.12
22 Sep 2021 $0.12 $0.00 0.00% 202,000 $0.12 $0.12 $0.12
21 Sep 2021 $0.12 $-0.01 -8.00% 431,270 $0.13 $0.13 $0.12

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
15 Sep 2021 Ross Dobinson Exercise 81 $11,472
Conversion of securities. 489,726 - rights
15 Sep 2021 Ross Dobinson Buy 81 $11,472
Conversion of securities.
15 Jun 2021 Ross Dobinson Exercise 81 $9,423
Conversion of securities. 571,670 - rights
15 Jun 2021 Ross Dobinson Buy 81 $9,423
Conversion of securities.
15 Mar 2021 Ross Dobinson Exercise 81 $12,701
Conversion of securities. 653,614 - rights
15 Mar 2021 Ross Dobinson Buy 81 $12,701
Conversion of securities.
04 Feb 2021 Ross Dobinson Issued 640 $100,480
Placement.
04 Feb 2021 Timothy Oldham Issued 63 $9,999
Placement.
04 Feb 2021 Geoffrey Brooke Issued 318 $50,000
Placement.
04 Feb 2021 Michael Kotsanis Issued 320 $50,240
Placement.
04 Feb 2021 Norman Gray Issued 127 $20,000
Placement.
03 Feb 2021 Timothy Oldham Buy 63 $10,000
Participation in share purchase plan.
03 Feb 2021 Michael Kotsanis Buy 191 $30,000
Participation in share purchase plan.
03 Feb 2021 Ross Dobinson Buy 191 $30,000
Participation in share purchase plan.
15 Jan 2021 Ross Dobinson Buy 80 $16,800
Conversion of securities.
15 Jan 2021 Ross Dobinson Exercise 80 $16,800
Conversion of securities. 735,558 - rights
15 Dec 2020 Ross Dobinson Buy 81 $14,749
Conversion of securities.
15 Dec 2020 Ross Dobinson Exercise 81 $14,749
Conversion of securities. 815,558 - rights
17 Nov 2020 Norman Gray Issued 699 $118,999
Issue of securities. 699,999 - rights

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Ross Dobinson Non-Executive ChairmanNon-Executive Director Jul 2012
Mr Dobinson is a founder and former CEO of Acrux. Ross has a background in investment banking and stockbroking. He is Member of Risk Committee.
Dr Geoffrey E.D Brooke Non-Executive Director Jun 2016
Dr Brooke founded GBS Venture Partners Pty Ltd in 1996 and has more than 20 years' venture capital experience. In January 2014, he reduced his involvement in GBS and is now adviser to the firm and its funds. Geoff was formally President of Medvest Inc. Geoff's experience includes company formation and acquisitions, as well as public listings on the NYSE, NASDAQ and ASX exchanges. He has been a founder, executive and Director of private and public companies. From 2009 until 2015, he was an independent Director of the Victoria WorkCover Authority. He is Chair of Risk Committee and Member of Human Capital Committee.
Dr Timothy Oldham Non-Executive Director Oct 2013
Dr Oldham has almost 20 years of life sciences business development, alliance management and sales and marketing experience in Europe, Asia and Australia. He was Executive Leader of Tijan Ventures and interim CEO, executive and Non-executive leadership services. He was previously CEO and Managing Director of Cell Therapies Pty Ltd and President of Asia Pacific for Hospira, Inc., having held a variety of senior management roles with Mayne Pharma Ltd prior to its acquisition by Hospira. These roles encompassed the development and commercialisation of generic pharmaceuticals, devices, biologics and cellular therapies. Tim began his business career as an engagement manager with McKinsey & Co. Tim is a Director of BioMelbourne Network Inc and has been chairman of the European Generic Medicines Association Biosimilars and Biotechnology Committee, a Director of the Alliance for Regenerative Medicine, a Director of the Generic Medicines Industry Association and a member of the Pharmaceutical Industry Strategy Group. He is Member of Risk Committee and Chair of the Human Capital Committee.
Mr Michael John Kotsanis Chief Executive OfficerManaging Director Nov 2014
Mr Kotsanis is executive with over 30 years of experience in the pharmaceutical industry and has senior leadership experience across the global pharmaceutical markets. He was formerly the Chief Commercial Officer and a Board Member of Synthon Holding BV. Prior to Synthon, he served as President, Europe, Middle East and Africa, for Hospira. Michael joined Hospira following its acquisition of Mayne Pharma in 2007, where he had served as President, Asia Pacific. He joined Mayne following their acquisition of FH Faulding in 2001, where he held responsibility for commercial activities of the pharmaceutical business in Australia and New Zealand. Prior to Faulding, Michael held a variety of sales and marketing positions with a German multinational pharmaceutical company over an 11 year period. Michael was formerly a Board Member of the European Generics Association and a Director of the Generic Medicines Industry Association of Australia. Michael is also a Non-executive Director of IDT Australia Limited.
Mr Donald Charles Brumley Non-Executive Director Jun 2021
Mr Brumley has 30 years' experience as a senior partner of Ernst & Young, Oceania. He has experience in IPOs, transactions and audit. Mr Brumley has advised and worked with Boards of organisations ranging from some of the companies in Australia to fast growing entrepreneurial and medium sized organisations. Mr Brumley was the Oceania IPO Leader at Ernst & Young and worked with clients listing on the Australian, US, UK and other Asian stock exchanges. He held positions as Biotech Markets Leader, National Leader of Strategic Growth Markets and on the Board of Partners of Ernst & Young.
Ms Joanna Johnson Chief Financial OfficerCompany Secretary Jun 2021
-
Joanna Johnson Chief Financial OfficerCompany Secretary
-
Charles O'Sullivan Portfolio Director
-
Felicia Colagrande Product Development and Technical Affairs Director
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
J P Morgan Nominees Australia Pty Limited 11,082,250 6.57%
DDH Graham Limited 9,767,196 5.79%
Citicorp Nominees My Limited 3,165,009 1.88%
MNM Capital Pty Ltd 2,915,672 1.73%
Ashwood River Pty Ltd 2,600,000 1.54%
Hishenk Pty Ltd 2,500,000 1.48%
Mr Ian Victor Lancini & Mrs Debra Ann Lancini 2,045,000 1.21%
Durbin Superannuation Pty Ltd 2,010,000 1.19%
Pacific Custodians 1,981,748 1.17%
Mr Ross Dobinson 1,715,537 1.03%
MNM Capital Pty Ltd (I) 1,640,647 0.97%
Mr Christopher Murray Abbott 1,600,000 0.95%
Neweconomy Com Au Nominees Pty Limited 1,551,270 0.92%
Asia Union Investments Ply Limited 1,500,000 0.89%
Morgan Stanley Australia Securities (Nomineei Pty Limited 1,228,991 0.73%
Adam Jamal 1,218,727 0.72%
Mr David Andrew Slobom & Mrs Linda Jane Slobom 1,218,513 0.72%
Ms Linlin Li 1,193,000 0.71%
Mr Gary Lester Hanikeri 1,150,000 0.68%
Dr Thomas Vui Chung Chai 1,120,601 0.66%

Profile

since

Note